Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher
Crossmark

Assessment of Health-Related Quality of Life in Patients with Psoriasis in Comparison with Normal Subjects in Shiraz Iran

Saman Farahangiz 1 , Negin Hadi 2 , * , Mahsa Naseri 3 , Ehsan Agah 3 and Ali Montazeri 4
Authors Information
1 Department of Community Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Community Medicine, Neurosciences Research Center, Research, Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Mental Health Research Group, Health Metrics Research Center, Iranian Institute for Health Sciences Research, ACECR, Tehran, IR Iran
Article information
  • Shiraz E-Medical Journal: April 01, 2014, 15 (2); e20589
  • Published Online: April 20, 2014
  • Article Type: Research Article
  • Received: February 16, 2014
  • Revised: March 1, 2014
  • Accepted: March 22, 2014
  • DOI: 10.17795/semj20589

To Cite: Farahangiz S, Hadi N, Naseri M, Agah E, Montazeri A. Assessment of Health-Related Quality of Life in Patients with Psoriasis in Comparison with Normal Subjects in Shiraz Iran, Shiraz E-Med J. 2014 ; 15(2):e20589. doi: 10.17795/semj20589.

Abstract
Copyright © 2014, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol. 1996; 34(5 Pt 2): 911-4[PubMed]
  • 2. Stern RS. Psoriasis. Lancet. 1997; 350(9074): 349-53[DOI][PubMed]
  • 3. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001; 26(4): 314-20[PubMed]
  • 4. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010; 146(1): 46-54[DOI][PubMed]
  • 5. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006; 4: 35[DOI][PubMed]
  • 6. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41(3 Pt 1): 401-7[PubMed]
  • 7. Mahajan R, Kanwar AJ, Kaur I. Assessing quality of life in patients with psoriasis and its improvement with treatment. J Eur Acad Dermatol Venereol. 2012; 26(5): 661-2[DOI][PubMed]
  • 8. Pakran J, Riyaz N, Nandakumar G. Determinants of quality of life in psoriasis patients: a cluster analysis of 50 patients. Indian J Dermatol. 2011; 56(6): 689-93[DOI][PubMed]
  • 9. Lin TY, See LC, Shen YM, Liang CY, Chang HN, Lin YK. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. 2011; 34(2): 186-96[PubMed]
  • 10. Manjula VD, Sreekiran S, Saril PS, Sreekanth MP. A study of psoriasis and quality of life in a tertiary care teaching hospital of kottayam, kerala. Indian J Dermatol. 2011; 56(4): 403-6[DOI][PubMed]
  • 11. Valenzuela F, Silva P, Valdes MP, Papp K. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermosifiliogr. 2011; 102(10): 810-6[DOI][PubMed]
  • 12. Grozdev I, Kast D, Cao L, Carlson D, Pujari P, Schmotzer B, et al. Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol. 2012; 132(4): 1111-6[DOI][PubMed]
  • 13. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013; 7: 199-205[DOI][PubMed]
  • 14. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004; 9(2): 140-7[DOI][PubMed]
  • 15. Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003; 4(12): 833-42[PubMed]
  • 16. Bohm D, Stock Gissendanner S, Bangemann K, Snitjer I, Werfel T, Weyergraf A, et al. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol. 2013; 27(2): 220-6[DOI][PubMed]
  • 17. Hrehorow E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012; 92(1): 67-72[DOI][PubMed]
  • 18. Miniszewska J, Juczynski Z, Ograczyk A, Zalewska A. Health-related quality of life in psoriasis: important role of personal resources. Acta Derm Venereol. 2013; 93(5): 551-6[DOI][PubMed]
  • 19. Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial. J Dermatol. 2012; 39(9): 761-9[DOI][PubMed]
  • 20. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010; 63(3): 457-65[DOI][PubMed]
  • 21. Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life. Ann Dermatol. 2010; 22(4): 389-96[DOI][PubMed]
  • 22. Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009; 219(3): 239-49[DOI][PubMed]
  • 23. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005; 14(3): 875-82[PubMed]
  • 24. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004; 45(3): 155-9[DOI][PubMed]
  • 25. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005; 23(4): 681-94[DOI][PubMed]
  • 26. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005; 6(6): 383-92[PubMed]
  • 27. Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011; 50(7): 783-92[DOI][PubMed]
  • 28. Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A. Psoriasis affects patient's quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med. 2012; 37(3): 84-8[PubMed]
  • 29. Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol. 2000; 43(5 Pt 1): 803-8[DOI][PubMed]
  • 30. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004; 51(5): 704-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments